ASCO

08/02/2016

JCP Editors

Moderator Robin Zon, MD, FACP, FASCO, Michiana Hematologu Oncology PC, Chair of the ASCO Clinical Pathways Task Force, started off by providing a brief history of clinical pathways in oncology. Starting in 1985, she...

...

08/02/2016

Journal of Clinical Pathways

Daratumumab More Cost Effective for Multiple Myeloma Treatment

06/13/2016

JCP Editors

Daratumumab may be the most cost-effective treatment option for patients with multiple myeloma (MM) compared with other novel therapies, according to a poster presented at the 2016 American Society of Clinical...

...

06/13/2016

Journal of Clinical Pathways

NCCN CEO Compares Evidence Blocks With Other Tools to Assess Value of Cancer Care Treatments

04/01/2016

JCP Editors

In a session at their 21st Annual Meeting in Hollywood, FL, National Comprehensive Cancer Network (NCCN) CEO Robert W Carlson, MD, discussed how NCCN Evidence Blocks stack up against other tools currently available...

In a...

04/01/2016

Journal of Clinical Pathways

ASCO Endorses EAU Guidelines for Muscle-Invasive, Metastatic Bladder Cancer

03/24/2016

JCP Editors

The American Society of Clinical Oncology (ASCO) has endorsed guidelines established by the European Association of Urology (EAU) for the treatment of muscle-invasive bladder cancer (MIBC) and metastatic bladder...

The...

03/24/2016

Journal of Clinical Pathways

Cabozantinib Bests Everolimus for Treatment of Advanced Renal Cell Carcinoma

01/12/2016

JCP Editors

Cabozantinib improves progression-free survival in patients with advanced renal cell carcinoma, according to an ongoing clinical trial comparing the drug with everolimus, an immunosuppressant that is the current...

...

01/12/2016

Journal of Clinical Pathways

Research in Review

ASCO Updates Antiemetic Guidelines to Include New Agent

12/11/2015

JCP Editors

The American Society of Clinical Oncology (ASCO) issued updated antiemetic guidelines recommending that patients who receive highly emetogenic chemotherapy regimens be offered a 3-drug combination of a neurokinin 1...

The...

12/11/2015

Journal of Clinical Pathways